MOTS-c (human)

Name: MOTS-c (human)
Brand: MedChemExpress
SKU: HY-P2048
Rating: 4.5 (1 reviews)

Cat. No.: HY-P2048 Purity: 99.90%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

MOTS-c (human) is a blood-brain barrier-penetrating, mitochondrial-derived peptide that modulates the AMPK/PGC-1α pathway to enhance insulin sensitivity. MOTS-c (human) inhibits the folate cycle and de novo purine synthesis, increases AICAR levels to activate AMPK, and then regulates the Nrf2/Keap1 antioxidant pathway and inhibits the NF-κB inflammatory pathway, while promoting mitochondrial biogenesis and energy metabolism. MOTS-c (human) has the effects of improving glucose and lipid metabolism, anti-oxidative stress, anti-inflammatory and neuroprotection, and can be used in the study of type 2 diabetes, traumatic brain injury, inflammatory diseases and aging-related metabolic disorders.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

MOTS-c (human) Chemical Structure

CAS No. : 1627580-64-6

Size	Stock	Quantity
Free Sample (0.1 - 0.2 mg)	Apply Now
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	Get quote
200 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of MOTS-c (human):

MOTS-c(human) acetate In-stock

1 Publications Citing Use of MCE MOTS-c (human)

•Maastricht University. 2025.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All GLUT Isoform Specific Products:

View All Isoforms

GLUT1 GLUT2 GLUT3 GLUT4

View All AMPK Isoform Specific Products:

View All Isoforms

NUAK1 NUAK2 AMPK AMPK α1β1γ1 AMPK α2β1γ1 AMPK α1β2γ1 AMPK α2β2γ1 BRSK1 BRSK2 HUNK AMPKα

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

GLUT4

AMPK

AICAR

In Vitro

Recent advances in high-resolution sequencing have led to the discovery of unique peptides derived from the mitochondrial genome. Eight peptides have been identified: humanin, the mitochondrial open reading frame of 12S tRNA-c (MOTS-c), and six small peptides (humanin-like peptides (SHLP1-6)). All of these peptides are released from mitochondria into the cytoplasm and are associated with extended lifespan and cell viability, reduced apoptosis, and other beneficial functions^[1].
MOTS-c (human) (10 μM; 24-72 h) activates AMPK (Thr172 phosphorylation) and the expression of downstream antioxidant proteins Nrf2 and Keap1, and inhibits the phosphorylation of MAPKs (ERK, JNK, P38) in HEK293 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:	HEK293 cells
Concentration:	10 μM
Incubation Time:	24-72 h
Result:	Significantly increased phosphorylation of AMPK at Thr172 and protein levels of Nrf2 and Keap1, while reducing phosphorylation of ERK, JNK, and P38. Resulted activation of AMPK by densitometric quantification, with a 2-fold increase in p-AMPK/AMPK ratio compared to control. Attenuated these effects by co-treatment with the AMPK inhibitor.

In Vivo

MOTS-c (human) (25-50 mg/kg; ip; once daily; 21 days) can reduce neurological deficits and inhibit the HMGB1/TLR4/NF-κB inflammatory pathway in brain tissue in a traumatic brain injury model in male C57BL/6 mice^[2].
MOTS-c (human) (5 mg/kg; ip; twice daily; 4 days) can reduce inflammation associated with obesity and insulin resistance by recruiting IL-6 and TNF-α in an acute treatment model in male CD-1 mice^[2].
MOTS-c (human) (50 mg/kg; ip; once a day; single dose) can reduce paw licking time and inhibit the expression of spinal p-ERK/p-JNK/p-P38 and c-fos in the formalin inflammation model of male ICR mice, exerting anti-nociceptive and anti-inflammatory effects^[3].
MOTS-c (human) (0.5 mg/kg; ip; once a day; 8 weeks) can reduce fasting blood glucose, glycosylated serum protein and blood lipid levels, improve myocardial ultrastructural damage and activate myocardial AMPK/Nrf2 antioxidant pathway^[4] in the male Sprague-Dawley rat type 2 diabetes model^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL/6 mice (6-8-week-old) with controlled-cortical impact (CCI)-induced traumatic brain injury model^[2]
Dosage:	25 mg/kg, 50 mg/kg (saline)
Administration:	Intraperitoneal injection, once daily, for 21 days starting 1 hour post-injury
Result:	At 50 mg/kg, MOTS-c reduced neurological severity scores (NSS) by 45% and improved rotarod performance (latency increased by 50%) compared to injured controls. Brain tissue analysis showed reduced HMGB1 expression (30% decrease), TLR4/NF-κB pathway inhibition, and lower pro-inflammatory cytokines (TNF-α, IL-6) in the ipsilateral cortex. OBB-NC formulation (3 mg/kg) showed comparable effects with enhanced BBB penetration.

Animal Model:	Male ICR mice (25-30 g, 6-week-old) with Formalin-induced paw inflammation model^[3]
Dosage:	50 mg/kg (saline)
Administration:	Intraperitoneal injection, 1 hour before formalin challenge, single dose
Result:	Significantly reduced licking time in the late phase (phase II, 11-40 min) by 60% compared to vehicle controls. Immunohistochemistry revealed decreased c-fos positive cells (40% reduction) in the spinal dorsal horn, with Western blot confirming suppressed phosphorylation of ERK (Thr202/Tyr204), JNK (Thr183/Tyr185), and P38 (Thr180/Tyr182) by 30-50%. The AMPK inhibitor Compound C abolished these effects.

Animal Model:	Male Sprague-Dawley rats (220-240 g, 7-week-old) with high-fat diet/streptozotocin-induced type 2 diabetes model^[4]
Dosage:	0.5 mg/kg (saline)
Administration:	Intraperitoneal injection, once daily, for 8 weeks
Result:	Significantly decreased fasting blood glucose (FBG) by 35%, HOMA-IR by 40%, and plasma triglycerides (TG)/total cholesterol (TC) by 25-30% compared to diabetic controls. Reduced mitochondrial swelling and cristae damage, with increased SOD/GSH activity and upregulated p-AMPK, Nrf2, and Keap1 protein expression in the heart. Combined with exercise, MOTS-c further enhanced glucose disposal and attenuated oxidative stress (MDA reduction by 50%).

Molecular Weight

2174.59

Formula

C₁₀₁H₁₅₂N₂₈O₂₂S₂

CAS No.

1627580-64-6

Appearance

Solid

Color

White to off-white

Sequence

Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg

Sequence Shortening

MRWQEMGYIFYPRKLR

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H₂O : ≥ 100 mg/mL (45.99 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.4599 mL	2.2993 mL	4.5986 mL
5 mM	0.0920 mL	0.4599 mL	0.9197 mL
10 mM	0.0460 mL	0.2299 mL	0.4599 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 99.90%

Select Batch:

Data Sheet (282 KB) SDS (254 KB)

COA (247 KB) RP-HPLC (109 KB) MS (240 KB) Elemental Analysis Report (106 KB)

Handling Instructions (2659 KB)

References

[1]. Mohtashami Z, et al. MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases. Int J Mol Sci. 2022 Oct 9;23(19):11991. [Content Brief]

[2]. Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015 Mar 3;21(3):443-54. [Content Brief]

[3]. Yin X, et al. The intraperitoneal administration of MOTS-c produces antinociceptive and anti-inflammatory effects through the activation of AMPK pathway in the mouse formalin test. Eur J Pharmacol. 2020 Mar 5;870:172909. [Content Brief]

[4]. Tang M, et al. The role of MOTS-c-mediated antioxidant defense in aerobic exercise alleviating diabetic myocardial injury. Sci Rep. 2023 Nov 13;13(1):19781. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O	1 mM	0.4599 mL	2.2993 mL	4.5986 mL	11.4964 mL
	5 mM	0.0920 mL	0.4599 mL	0.9197 mL	2.2993 mL
	10 mM	0.0460 mL	0.2299 mL	0.4599 mL	1.1496 mL
	15 mM	0.0307 mL	0.1533 mL	0.3066 mL	0.7664 mL
	20 mM	0.0230 mL	0.1150 mL	0.2299 mL	0.5748 mL
	25 mM	0.0184 mL	0.0920 mL	0.1839 mL	0.4599 mL
	30 mM	0.0153 mL	0.0766 mL	0.1533 mL	0.3832 mL
	40 mM	0.0115 mL	0.0575 mL	0.1150 mL	0.2874 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

MOTS-c (human) Related Classifications

Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

MOTS-c (human)1627580-64-6ApoptosisGLUTAMPKGlucose transporter AMP-activated protein kinaseInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

MOTS-c (human)

Customer Review

Other Forms of MOTS-c (human):

MOTS-c (human) Related Antibodies

1 Publications Citing Use of MCE MOTS-c (human)

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All GLUT Isoform Specific Products:

View All AMPK Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

MOTS-c (human) Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

MOTS-c (human) Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report